Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $56.24 is 19.52% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 57.04||$ 74.75|
|Low:||$ 54.88||$ 47.055|
Company Description (as filed with the SEC)
We are an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye. Our strategy is to commercialize Rhopressa®, approved by the FDA on December 18, 2017, in North American markets and advance our product candidate, RoclatanTM, to regulatory approval. We are in the process of hiring a commercial team that will include approximately 100 sales representatives to target approximately 12,000 high prescribing eye-care professionals throughout the United States. This sales force will initially be responsible for sales of Rhopressa®, and will also be responsible for sales of RoclatanTM, if approved. Our strategy also includes developing our business outside of North America, including obtaining regulatory approval in Europe and Japan on our own for Rhopressa® and RoclatanTM. ... More ...
Nasdaq Official Price
Oct. 15, 2018
Oct. 15, 2018